NO20092059L - Anvendelse av MTKI1 for a behandle eller forhindre benkreft - Google Patents

Anvendelse av MTKI1 for a behandle eller forhindre benkreft

Info

Publication number
NO20092059L
NO20092059L NO20092059A NO20092059A NO20092059L NO 20092059 L NO20092059 L NO 20092059L NO 20092059 A NO20092059 A NO 20092059A NO 20092059 A NO20092059 A NO 20092059A NO 20092059 L NO20092059 L NO 20092059L
Authority
NO
Norway
Prior art keywords
bone
bone cancer
cancer
mtki1
treat
Prior art date
Application number
NO20092059A
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Theo Frans Meert
Timothy Pietro Suren Perera
Michel Marie Francois Janicot
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20092059L publication Critical patent/NO20092059L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Den foreliggende oppfinnelsen angår funnet at makrocyklisk quinazolinderivat 4,6-etandiylidenpyrimido[4,5-b][6,1,12]benzoksadiazacyclo-pentadecin, 17-brom-8,9,10,11,12,13,14,19-octahydro-20-metoksy-13-metyl-, beskrevet som forbindelse 22 i PCT publikasjon WO2004/105765, er anvendelig i produksjonen av et medikament for behandlingen eller forebyggingen av beinkreft og fremgangsmåte for å drepe beincreftceller, inkludert osteosarkomer, kondrosarkomer, myelom, beinlidelse og osteolytisk beinmetastaser fra andre primærsteder. Den tilveiebringer følgelig fremgangsmåter for å behandle, forebygge, forsinke eller lindre beinkreft, eller for å forebygge og behandle beintap forbundet med kreftmetastaser.
NO20092059A 2006-10-27 2009-05-27 Anvendelse av MTKI1 for a behandle eller forhindre benkreft NO20092059L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86316706P 2006-10-27 2006-10-27
EP06123060 2006-10-27
US97618807P 2007-09-28 2007-09-28
PCT/EP2007/061501 WO2008049904A2 (en) 2006-10-27 2007-10-25 Use of mtki 1 for treating or preventing bone cancer

Publications (1)

Publication Number Publication Date
NO20092059L true NO20092059L (no) 2009-06-29

Family

ID=39066650

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092059A NO20092059L (no) 2006-10-27 2009-05-27 Anvendelse av MTKI1 for a behandle eller forhindre benkreft

Country Status (11)

Country Link
EP (1) EP2101782A2 (no)
JP (1) JP2010507628A (no)
KR (1) KR20090086977A (no)
AU (1) AU2007310845A1 (no)
BR (1) BRPI0718021A2 (no)
CA (1) CA2664165A1 (no)
EA (1) EA200970420A1 (no)
IL (1) IL198344A0 (no)
MX (1) MX2009004438A (no)
NO (1) NO20092059L (no)
WO (1) WO2008049904A2 (no)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8603801A1 (es) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
GB0507347D0 (en) * 2005-04-12 2005-05-18 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
MX2009004438A (es) 2009-05-11
KR20090086977A (ko) 2009-08-14
JP2010507628A (ja) 2010-03-11
IL198344A0 (en) 2010-02-17
EA200970420A1 (ru) 2009-12-30
EP2101782A2 (en) 2009-09-23
AU2007310845A1 (en) 2008-05-02
BRPI0718021A2 (pt) 2013-11-12
WO2008049904A2 (en) 2008-05-02
CA2664165A1 (en) 2008-05-02
WO2008049904A3 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
WO2008147864A3 (en) Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
MX2015007556A (es) Derivados de manosa para tratar infecciones bacterianas.
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
EA025302B8 (ru) Модуляторы кальциевого канала, активируемого высвобождением кальция, представляющие собой производные пиразола, и способы лечения немелкоклеточного рака легких
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
ATE438404T1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
IL182218A0 (en) Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
WO2008103277A3 (en) Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
WO2008013987A3 (en) N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
EA201290356A1 (ru) Композиции для лечения тошноты и рвоты центрального происхождения
WO2008076949A3 (en) Quinazoline derivatives and methods of treatment
EA201170834A1 (ru) Соединения, пригодные для ингибирования chk1
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
EA201100874A1 (ru) Соединения для лечения рака
MX2010004857A (es) Compuestos de benzodiazepinona utiles en el tratamiento de afecciones de la piel.
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
EA200870454A1 (ru) Способ ингибирования c-kit киназы

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application